Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of PAVmed Inc (NASDAQ: PAVM) was $0.35 for the day, up 4.57% from the previous closing price of $0.33. In other words, the price has increased by $4.57 from its previous closing price. On the day, 0.49 million shares were traded. PAVM stock price reached its highest trading level at $0.3564 during the session, while it also had its lowest trading level at $0.3261.
Ratios:
Our analysis of PAVM’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.52 and its Current Ratio is at 0.52. In the meantime, Its Debt-to-Equity ratio is 0.23 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on March 30, 2021, initiated with a Overweight rating and assigned the stock a target price of $8.
On November 05, 2020, Ascendiant Capital Markets started tracking the stock assigning a Buy rating and target price of $5.
On June 28, 2018, Maxim Group started tracking the stock assigning a Buy rating and target price of $5.Maxim Group initiated its Buy rating on June 28, 2018, with a $5 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 12 ’24 when JAMES L. COX bought 9,469 shares for $0.78 per share.
JAMES L. COX bought 38,095 shares of PAVM for $32,739 on Dec 09 ’24. On Dec 06 ’24, another insider, JAMES L. COX, who serves as the Director of the company, bought 15,600 shares for $1.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PAVM now has a Market Capitalization of 9717052 and an Enterprise Value of 30828980. As of this moment, PAVmed’s Price-to-Earnings (P/E) ratio for their current fiscal year is 0.30. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.16 while its Price-to-Book (P/B) ratio in mrq is 0.54. Its current Enterprise Value per Revenue stands at 30.224 whereas that against EBITDA is -1.161.
Stock Price History:
The Beta on a monthly basis for PAVM is 1.11, which has changed by -0.67156863 over the last 52 weeks, in comparison to a change of 0.14151978 over the same period for the S&P500. Over the past 52 weeks, PAVM has reached a high of $1.25, while it has fallen to a 52-week low of $0.30. The 50-Day Moving Average of the stock is -19.79%, while the 200-Day Moving Average is calculated to be -40.51%.
Shares Statistics:
PAVM traded an average of 428.85K shares per day over the past three months and 529920 shares per day over the past ten days. A total of 26.68M shares are outstanding, with a floating share count of 20.45M. Insiders hold about 23.36% of the company’s shares, while institutions hold 9.08% stake in the company. Shares short for PAVM as of 1761868800 were 256466 with a Short Ratio of 0.95, compared to 1759190400 on 220764. Therefore, it implies a Short% of Shares Outstanding of 256466 and a Short% of Float of 1.0.
Earnings Estimates
A comprehensive evaluation of PAVmed Inc (PAVM) is underway, with the input of 1.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.2, with high estimates of -$0.2 and low estimates of -$0.2.
Analysts are recommending an EPS of between -$0.55 and -$0.55 for the fiscal current year, implying an average EPS of -$0.55. EPS for the following year is -$0.77, with 1.0 analysts recommending between -$0.77 and -$0.77.
Revenue Estimates
Based on 2 analysts’ estimates, the company’s revenue will be $490k in the next fiscal year. The high estimate is $500k and the low estimate is $480k.
